ANGLE plc ("ANGLE" Or "The Company") Corporate Collaboration With Large Pharmaceutical Company

GUILDFORD, United Kingdom, Jan. 8, 2015 /PRNewswire/ -- ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech company, is delighted to announce that it has agreed a collaboration with a subsidiary of a large pharmaceutical company (the "Collaborator") to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with the Collaborator's single cell analysis system.

The Collaborator Group is a multinational pharmaceutical, biotechnology and diagnostics company with multi-billion dollar revenues. The name of the Collaborator and other terms of the collaboration are not disclosed.

The Collaborator's cell analysis system is best deployed on sub-populations of cells that have been pre-enriched (concentration of target cells and reduction of non-target cells such as white blood cells).  The Collaborator wishes to evaluate the use of the Parsortix system as a standard pre-enrichment system for their single cell analysis system.  ANGLE's key opinion leaders have previously reported that the Parsortix system harvests a high purity of CTCs and was 30 times purer than a leading antibody-based system.  The first phase is a proof-of-principle of the Collaborator's system working with Parsortix.

ANGLE's patented Parsortix system can harvest very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells.  The aim of the resulting liquid biopsy (simple blood test) is to enable the investigation of mutations in the patient's cancer for personalised cancer care.  The Parsortix system is "open-source" and has been designed to work with all existing analytical procedures in the same way that the existing solid biopsy provides cancer cells for a wide variety of analytical procedures.

ANGLE's commercialisation strategy is to establish a series of partnerships with multiple leading diagnostic companies to offer a complete solution to the oncologist.  ANGLE believes this is the optimal approach for unlocking the multi-billion dollar worldwide market available to the Company and its potential strategic partners.

Partners will be selected for their specialist technical capabilities enabling new high medical utility applications and/or their market strength and existing installed base of diagnostic systems enabling accelerated market adoption of the Parsortix system.

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"We believe ANGLE's Parsortix system is the leading system for harvesting circulating tumour cells from blood for analysis in personalised cancer care.  The combination of our system with the Collaborator's single cell analysis system would produce a powerful analytical capability, initially for researchers and ultimately for clinicians creating a major commercial opportunity for ANGLE." 

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

Notes for editors

About ANGLE plc     

ANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology, known as the Parsortix system, harvests the cells of interest through a liquid biopsy, with the patient only experiencing a simple blood test. Parsortix is the subject of two granted US patents and three extensive families of patents being progressed worldwide. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The Parsortix system is established with strong positive evaluations from leading cancer research centres and is working with these cancer centres to demonstrate key applications. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the US.

The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.

ANGLE has established formal collaborations with world-class cancer centres and is working with these cancer centres to demonstrate key applications for its Parsortix non-invasive cancer diagnostic system as a liquid biopsy.  Details are available here http://www.angleplc.com/the-company/collaborators/

In addition to cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future.

ANGLE began trading on the AIM market of the London Stock Exchange in March 2004 under the ticker symbol AGL. For more information visit www.angleplc.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/angle-plc-angle-or-the-company-corporate-collaboration-with-large-pharmaceutical-company-300017774.html

SOURCE ANGLE plc

Copyright 2015 PR Newswire